Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ATI-2231 |
Synonyms | |
Therapy Description |
Limited information is currently available on ATI-2231, a putative MAPKAPK2 (MK2) inhibitor (Apr 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ATI-2231 | ATI2231|ATI 2231 | Limited information is currently available on ATI-2231, a putative MAPKAPK2 (MK2) inhibitor (Apr 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05791474 | Phase Ib/II | Capecitabine + Denosumab ATI-2231 + Capecitabine ATI-2231 Bisphosphonate + Capecitabine | ATI-2231 With in Advanced Solid Tumor Malignancies Followed by ATI-2231 in Combination With Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer | Withdrawn | 0 |